Skip to main content

son-1010

Generic: Interleukin 12 (IL-12)·Code: SON-1010

son-1010: 2 clinical trials tracked.

son-1010 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about son-1010, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

NCT05756907Registry updated 2026-02-03·Phase 1/Phase 2
Terminated

Primary endpoint: To evaluate the safety and tolerability of SON-1010 in combination with Atezolizumab

Interventionalopen40 targetStarted 2023-09Completion 2026-016 sites · Australia, United StatesSonnet BioTherapeutics

A Phase 1, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-1010 (IL12-FHAB) in Adult Patients With Advanced Solid Tumors.

NCT05352750Registry updated 2026-02-03·Phase 1
Active, not recruiting

Primary endpoint: To evaluate the safety and tolerability of SON-1010

Interventionalopen42 targetStarted 2022-04Completion 2026-061 site · United StatesSonnet BioTherapeutics